Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical experience with the implantable atrial defibrillator (atrioverter) in patients with atrial fibrillation
Autore:
Seidl, K; Jung, W; Schwacke, H; Wolpert, C; Drogemuller, A; Spehl, S; Schumacher, B; Esmailzadeh, B; Werling, C; Senges, J;
Indirizzi:
Herzzentrum Ludwigshafen, D-67063 Ludwigshafen, Germany Herzzentrum Ludwigshafen Ludwigshafen Germany D-67063 wigshafen, Germany
Titolo Testata:
ZEITSCHRIFT FUR KARDIOLOGIE
fascicolo: 8, volume: 88, anno: 1999,
pagine: 574 - 581
SICI:
0300-5860(199908)88:8<574:CEWTIA>2.0.ZU;2-6
Fonte:
ISI
Lingua:
GER
Soggetto:
ENERGY INTRACARDIAC CARDIOVERSION; MANAGEMENT; STRATEGIES; THRESHOLD; FLUTTER; HUMANS;
Keywords:
implantable atrial defibrillator; atrial fibrillation; proarrhythmia; complications;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Seidl, K Herzzentrum Ludwigshafen, Bremserstr 79, D-67063 Ludwigshafen, Germany Herzzentrum Ludwigshafen Bremserstr 79 Ludwigshafen Germany D-67063
Citazione:
K. Seidl et al., "Clinical experience with the implantable atrial defibrillator (atrioverter) in patients with atrial fibrillation", Z KARDIOL, 88(8), 1999, pp. 574-581

Abstract

Due to the limited efficacy of drug therapy in atrial fibrillation and thehigh rate of recurrence, strong efforts were made to find non-pharmacological strategies. For three years now, the implantable atrial defibrillator Metrix(TM) from InControl has been available as an alternative therapy. FromOctober 1995 to the present the atrial defibrillator was implanted in 179 patients worldwide. The sensitivity of the system and its algorithms to detect atrial fibrillation is 90 %; the specifity to detect sinus rhythm 100 %. In 121 of 179 patients, 748 episodes of spontaneous atrial fibrillation were treated with 2.4 shocks per episode. No proarrhythmic event or stroke was seen. A cardioversion to sinus rhythm could be achieved in 95 % of patients; the overall clinical success rate was 88 %. In 7 % of all patients, early recurrence of atrial fibrillation (ERAF) occurred that could not be converted into stable sinus rhythm after further cardioversions and antiarrhythmic therapy. In 4.1 % there were lead-related complications, in 3 patientsthe device had to be explanted because of ineffective therapy, and in 3 patients the device had to be changed because of loss of telemetry or early depletion of battery. In 8 patients, postoperative complications were seen (infections, pneumothorax and thrombosis of the subclavian vein). Overall, the implantable atrial defibrillator Metrix(TM) is an effective and safe alternative in treating atrial fibrillation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 09:14:39